Drug Type Bispecific antibody |
Synonyms NB 202, NB202 |
Target |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TIM3 inhibitors(Hepatitis A virus cellular receptor 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 22 Mar 2024 |